1. Home
  2. LQDA vs DNN Comparison

LQDA vs DNN Comparison

Compare LQDA & DNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • DNN
  • Stock Information
  • Founded
  • LQDA 2004
  • DNN 1954
  • Country
  • LQDA United States
  • DNN Canada
  • Employees
  • LQDA N/A
  • DNN N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • DNN Other Metals and Minerals
  • Sector
  • LQDA Health Care
  • DNN Basic Materials
  • Exchange
  • LQDA Nasdaq
  • DNN Nasdaq
  • Market Cap
  • LQDA 1.9B
  • DNN 1.8B
  • IPO Year
  • LQDA 2018
  • DNN 1997
  • Fundamental
  • Price
  • LQDA $23.15
  • DNN $3.06
  • Analyst Decision
  • LQDA Strong Buy
  • DNN Strong Buy
  • Analyst Count
  • LQDA 9
  • DNN 1
  • Target Price
  • LQDA $32.67
  • DNN $2.75
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • DNN 107.6M
  • Earning Date
  • LQDA 11-03-2025
  • DNN 11-06-2025
  • Dividend Yield
  • LQDA N/A
  • DNN N/A
  • EPS Growth
  • LQDA N/A
  • DNN N/A
  • EPS
  • LQDA N/A
  • DNN N/A
  • Revenue
  • LQDA $19,322,000.00
  • DNN $3,311,190.00
  • Revenue This Year
  • LQDA $424.31
  • DNN $197.76
  • Revenue Next Year
  • LQDA $359.32
  • DNN $54.87
  • P/E Ratio
  • LQDA N/A
  • DNN N/A
  • Revenue Growth
  • LQDA 30.20
  • DNN 12.14
  • 52 Week Low
  • LQDA $9.71
  • DNN $1.08
  • 52 Week High
  • LQDA $29.94
  • DNN $3.42
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 48.99
  • DNN 61.68
  • Support Level
  • LQDA $21.97
  • DNN $2.70
  • Resistance Level
  • LQDA $24.34
  • DNN $3.17
  • Average True Range (ATR)
  • LQDA 1.20
  • DNN 0.22
  • MACD
  • LQDA 0.05
  • DNN -0.01
  • Stochastic Oscillator
  • LQDA 40.98
  • DNN 56.02

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About DNN Denison Mines Corp (Canada)

Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.

Share on Social Networks: